Akari Therapeutics   Report issue

For profit Phase 3
Founded: London United Kingdom (2005)

Organization Overview

First Clinical Trial
2016
NCT02591862
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AKARI Therapeutics